Cargando…

Analysis of topoisomerase I expression and identification of predictive markers for efficacy of topotecan chemotherapy in small cell lung cancer

BACKGROUND: We evaluated topoisomerase I (TOPO1) expression in patients with small cell lung cancer (SCLC) and identified predictive factors for the efficacy of second‐line topotecan chemotherapy. METHODS: We retrospectively evaluated the records of SCLC patients treated in our department from Janua...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lv, Chunxin, Liu, Xiuju, Zheng, Qiwen, Chen, Hanxiao, Yang, Xue, Zhong, Jia, Wang, Yuyan, Duan, Jianchun, Wang, Zhijie, Bai, Hua, Wu, Meina, Zhao, Jun, Wang, Jie, Wang, Ziping, An, Tongtong, Zhuo, Minglei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons Australia, Ltd 2018
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6119620/ https://www.ncbi.nlm.nih.gov/pubmed/30058109 http://dx.doi.org/10.1111/1759-7714.12819

Ejemplares similares

Epidermal growth factor receptor variant III mutation in Chinese patients with squamous cell cancer of the lung
por: Duan, Jianchun, et al.
Publicado: (2015)

Clinical Characteristics and Outcomes of Patients With Primary Mediastinal Germ Cell Tumors: A Single-Center Experience
por: Wang, Lu, et al.
Publicado: (2020)

Quantification and Dynamic Monitoring of EGFR T790M in Plasma Cell-Free DNA by Digital PCR for Prognosis of EGFR-TKI Treatment in Advanced NSCLC
por: Wang, Zhijie, et al.
Publicado: (2014)

Detection and Clinical Significance of Intratumoral EGFR Mutational Heterogeneity in Chinese Patients with Advanced Non-Small Cell Lung Cancer
por: Bai, Hua, et al.
Publicado: (2013)

Efficacy and safety of pemetrexed maintenance chemotherapy for advanced non-small cell lung cancer in a real-world setting
por: Li, Jianjie, et al.
Publicado: (2021)

Alterations in EGFR and Related Genes following Neo-Adjuvant Chemotherapy in Chinese Patients with Non-Small Cell Lung Cancer
por: Wang, Shuhang, et al.
Publicado: (2013)

Influence of body mass index on the therapeutic efficacy of gemcitabine plus cisplatin and overall survival in lung squamous cell carcinoma
por: Zhong, Jia, et al.
Publicado: (2018)

A nomogram model to predict death rate among non-small cell lung cancer (NSCLC) patients with surgery in surveillance, epidemiology, and end results (SEER) database
por: Jia, Bo, et al.
Publicado: (2020)

Retrospective analysis of the effectiveness and tolerability of nab‐paclitaxel in Chinese elderly patients with advanced non‐small‐cell lung carcinoma
por: Wang, Shuhang, et al.
Publicado: (2020)

DNA Methylation status of Wnt antagonist SFRP5 can predict the response to the EGFR-tyrosine kinase inhibitor therapy in non-small cell lung cancer
por: Zhu, Jian, et al.
Publicado: (2012)

Nomogram to predict cause‐specific mortality in extensive‐stage small cell lung cancer: A competing risk analysis
por: Zhong, Jia, et al.
Publicado: (2019)

Survival analysis via nomogram of surgical patients with malignant pleural mesothelioma in the Surveillance, Epidemiology, and End Results database
por: Zhuo, Minglei, et al.
Publicado: (2019)

Nomogram model for predicting cause-specific mortality in patients with stage I small-cell lung cancer: a competing risk analysis
por: Li, Jianjie, et al.
Publicado: (2020)

Evaluation of different treatment strategies between right-sided and left-sided pneumonectomy for stage I–IIIA non-small cell lung cancer patients
por: Jia, Bo, et al.
Publicado: (2021)

Optimal first‐line treatment for advanced thymic carcinoma
por: Yang, Xue, et al.
Publicado: (2019)

Effects of Surgery on Survival of Early-Stage Patients With SCLC: Propensity Score Analysis and Nomogram Construction in SEER Database
por: Wang, Yuyan, et al.
Publicado: (2020)

ERβ localization influenced outcomes of EGFR-TKI treatment in NSCLC patients with EGFR mutations
por: Wang, Zhijie, et al.
Publicado: (2015)

Efficacy and Safety of Combination Treatment With Apatinib and Osimertinib After Osimertinib Resistance in Epidermal Growth Factor Receptor-Mutant Non-small Cell Lung Carcinoma—A Retrospective Analysis of a Multicenter Clinical Study
por: Yang, Xue, et al.
Publicado: (2021)

Quantification of mutant alleles in circulating tumor DNA can predict survival in lung cancer
por: Yang, Xue, et al.
Publicado: (2016)

Identification of plasma microRNA profiles for primary resistance to EGFR-TKIs in advanced non-small cell lung cancer (NSCLC) patients with EGFR activating mutation
por: Wang, Shuhang, et al.
Publicado: (2015)

Plasma cytokines interleukin-18 and C-X-C motif chemokine ligand 10 are indicative of the anti-programmed cell death protein-1 treatment response in lung cancer patients
por: Wang, Yida, et al.
Publicado: (2021)

The prevalence and real‐world therapeutic analysis of Chinese patients with KRAS‐Mutant Non‐Small Cell lung cancer
por: Chen, Hanxiao, et al.
Publicado: (2022)

Correlation among genetic variations of c-MET in Chinese patients with non-small cell lung cancer
por: Duan, Jianchun, et al.
Publicado: (2017)

Survival comparison of right and left side non‐small cell lung cancer in stage I–IIIA patients: A Surveillance Epidemiology and End Results (SEER) analysis
por: Jia, Bo, et al.
Publicado: (2019)

Bioavailability and pharmacokinetics of oral topotecan: a new topoisomerase I inhibitor.
por: Schellens, J. H., et al.
Publicado: (1996)

Topoisomerase I Inhibitors, Shikonin and Topotecan, Inhibit Growth and Induce Apoptosis of Glioma Cells and Glioma Stem Cells
por: Zhang, Feng-Lei, et al.
Publicado: (2013)

Characterization of Microbiota in Cancerous Lung and the Contralateral Non-Cancerous Lung Within Lung Cancer Patients
por: Zhuo, Minglei, et al.
Publicado: (2020)

Efficacy and safety of weekly intravenous nanoparticle albumin‐bound paclitaxel for non‐small cell lung cancer patients who have failed at least two prior systemic treatments
por: Duan, Jianchun, et al.
Publicado: (2017)

ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane‐based chemotherapy
por: Zhong, Jia, et al.
Publicado: (2019)

Metronomic Chemotherapy Based on Topotecan or Topotecan and Cyclophosphamide Combination (CyTo) in Advanced, Pretreated Ovarian Cancer
por: Wysocki, Piotr J., et al.
Publicado: (2023)

Structural and Dynamical Effects Induced by the Anticancer Drug Topotecan on the Human Topoisomerase I – DNA Complex
por: Mancini, Giordano, et al.
Publicado: (2010)

放Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification
por: Jia, Bo, et al.
Publicado: (2021)

Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma
por: Li, Junfeng, et al.
Publicado: (2023)

Three different mutations in the DNA topoisomerase 1B in Leishmania infantum contribute to resistance to antitumor drug topotecan
por: Rosa-Teijeiro, Chloé, et al.
Publicado: (2021)

A review of topotecan in combination chemotherapy for advanced cervical cancer
por: Robati, Minoo, et al.
Publicado: (2008)

Prediction of the VeriStrat test in first-line therapy of pemetrexed-based regimens for advanced lung adenocarcinoma patients
por: Jia, Bo, et al.
Publicado: (2020)

High‐fidelity of non‐small cell lung cancer xenograft models derived from bronchoscopy‐guided biopsies
por: Fu, Shuai, et al.
Publicado: (2015)

Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
por: Sorensen, M., et al.
Publicado: (1995)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Metagenome association study of the gut microbiome revealed biomarkers linked to chemotherapy outcomes in locally advanced and advanced lung cancer
por: Zhao, Zhe, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_soncl1d1k798d357gb7h03tkdr